Table 1. An analysis of demographic characteristics and biomarker fibrosis staging for each fibrosis stage as determined via MRE.
| Demographics and biomarker scoring |
Fibrosis stage based on MRE | P value | |||||
|---|---|---|---|---|---|---|---|
| Normal | Normal or inflammation | Stage ≥1 to ≤2 |
Stage >2 to <3 |
Stage ≥3 to <4 |
Stage ≥4 | ||
| Age (years) | 0.0323 | ||||||
| ≤35 | 12 (15.00) | 5 (12.82) | 2 (8.70) | 0 (0.00) | 2 (9.52) | 1 (4.76) | |
| 36–64 | 55 (68.75) | 21 (53.85) | 13 (56.52) | 4 (44.44) | 9 (42.86) | 9 (42.86) | |
| ≥65 | 13 (16.25) | 13 (33.33) | 8 (34.78) | 5 (55.56) | 10 (47.62) | 11 (52.38) | |
| Sex | 0.7371 | ||||||
| Male | 34 (42.50) | 18 (46.15) | 13 (56.52) | 5 (55.56) | 12 (57.14) | 11 (52.38) | |
| Female | 46 (57.50) | 21 (53.85) | 10 (43.48) | 4 (44.44) | 9 (42.86) | 10 (47.62) | |
| FIB-4 score | <0.0001 | ||||||
| No score (≤35 years) | 12 (15.00) | 5 (12.82) | 2 (8.70) | 0 (0.00) | 2 (9.52) | 1 (4.76) | |
| Advanced fibrosis excluded | 56 (70.00) | 19 (48.72) | 9 (39.13) | 5 (55.56) | 9 (42.86) | 2 (9.52) | |
| Further investigation needed | 8 (10.00) | 12 (30.77) | 9 (39.13) | 2 (22.22) | 6 (28.57) | 2 (9.52) | |
| Advanced fibrosis likely | 4 (5.00) | 3 (7.69) | 3 (13.04) | 2 (22.22) | 4 (19.05) | 16 (76.19) | |
| NFS score | <0.0001 | ||||||
| F0-F2 | 61 (76.25) | 18 (46.15) | 8 (34.78) | 3 (33.33) | 7 (33.33) | 1 (4.76) | |
| Indeterminate | 16 (20.00) | 20 (51.28) | 11 (47.83) | 5 (55.56) | 7 (33.33) | 4 (19.05) | |
| F3-F4 | 3 (3.75) | 1 (2.56) | 4 (17.39) | 1 (11.11) | 7 (33.33) | 16 (76.19) | |
The numbers in parentheses represent the percentage with regards to the column within each subcategory. P value for sex using Chi-Square test, others using Fisher’s Exact test since cross tabulations had >25% of cells with counts <5. MRE, magnetic resonance elastography; FIB-4, Fibrosis-4; NFS, NAFLD Fibrosis Score; NAFLD, non-alcoholic fatty liver disease.